Therapeutics Acquisition Corp. (RACA): Price and Financial Metrics


Therapeutics Acquisition Corp. (RACA)

Today's Latest Price: $14.20 USD

0.08 (0.57%)

Updated Jan 25 6:55pm

Add RACA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 260 in Financial Services (Enterprise)

See all "A" rated Strong Buy stocks

RACA Stock Price Chart Interactive Chart >

Price chart for RACA

RACA Price/Volume Stats

Current price $14.20 52-week high $21.44
Prev. close $14.12 52-week low $11.11
Day low $13.88 Volume 5,300
Day high $14.23 Avg. volume 14,400
50-day MA $14.05 Dividend yield N/A
200-day MA $0.00 Market Cap 199.38M

Therapeutics Acquisition Corp. (RACA) Company Bio


Therapeutics Acquisition Corp. focuses on merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify and acquire a business focusing on the healthcare industry. The company was founded in 2020 and is based in Boston, Massachusetts.


RACA Latest News Stream


Event/Time News Detail
Loading, please wait...

RACA Latest Social Stream


Loading social stream, please wait...

View Full RACA Social Stream

Latest RACA News From Around the Web

Below are the latest news stories about Therapeutics Acquisition Corp that investors may wish to consider to help them evaluate RACA as an investment opportunity.

Cerevance Appoints David Lubner to Board of Directors

Life sciences industry veteran brings more than 25 years of financial and operational experienceBOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Ve...

Yahoo | December 8, 2020

Read More 'RACA' Stories Here

RACA Price Returns

1-mo N/A
3-mo 9.15%
6-mo -5.33%
1-year N/A
3-year N/A
5-year N/A
YTD 2.01%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9367 seconds.